EUCTR2006-006550-96-GB进行中（未招募）1 期
Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus
TrialNet Study Group0 个研究点目标入组 562 人开始时间: 2009年4月9日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 562
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Have a proband* with T1DM.
- •2. If the proband is a sibling, parent or a child, the study participant must be 3 - 45 years of age. If the proband is a second or third degree relative (i.e. Niece, Nephew, Aunt, Uncle, Grandparent, Cousin), the study participant must be 3-20 years of age.
- •3. Willing to sign Informed Consent Form.
- •4. Has normal glucose tolerance on an OGTT performed within 7 weeks prior to randomization. If previous abnormal glucose tolerance, has had two consecutive OGTT with normal glucose tolerance.
- •5. mIAA confirmed positive within the previous six months.
- •6. At least one other antibody present on two separate samples, one of which was drawn within the past six months.
- •* A proband is an individual diagnosed with diabetes before age 40 and started on insulin therapy within 1-year of diagnosis. Probands considered to have type 1 diabetes by their physician who do not meet this definition will be referred to the TrialNet Eligibility Committee.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Does not satisfy the above inclusion criteria.
- •2. Has severe active disease, e.g. chronic active hepatitis, severe cardiac, pulmonary, renal, hepatic, immune deficiency and/or disease that is likely to limit life expectancy or lead to therapies such as immunosuppression during the time of the study.
- •3. Prior participation in a clinical trial for secondary prevention of T1DM.
- •4. History of treatment with insulin or oral hypoglycemic agent.
- •5. History of therapy with immunosuppressive drugs or non-physiologic glucocorticoids within the past two years for a period of more than three months.
- •6. Ongoing use of medications known to influence glucose tolerance, i.e. sulfonylureas, growth hormone, metformin, anticonvulsants, thiazide or potassium depleting diuretics, beta adrenergic blockers, niacin. Subjects on such medications should be changed to a suitable alternative, if available, and will become eligible one month after medication is discontinued.
- •7. Pregnant or intends to become pregnant while on study or lactating.
- •8. Deemed unlikely or unable to comply with the protocol.
- •9. OGTT that reveals abnormal glucose tolerance unless two subsequent consecutive OGTT have normal glucose tolerance. Abnormal glucose tolerance is defined as:
- •fasting plasma glucose = 110 mg/dL (6.1 mmol/l), AND/OR
- •2 hour plasma glucose = 140 mg/dL (7.8 mmol/l) AND/OR
- •30, 60, or 90 minute plasma glucose = 200 mg/dL (11.1 mmol/l)
- •10 . Subject has HLA DQA1*0102, DQB1*0602 haplotype.
研究者
相似试验
进行中（未招募）
1 期
Oral Insulin for Prevention of Diabetes in People with Family Members with Type 1 DiabetesOral insulin is to be used for the prevention of type 1 diabetes mellitus in relatives at risk of developing the disease.MedDRA version: 18.0Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2006-006550-96-DETrialNet Coordinating Center400
进行中（未招募）
1 期
Oral insulin for prevention of diabetes in relatives at risk for type 1 diabetes mellitus - NDprevention of type 1 diabetes mellitus in subjects at risk for T1DMMedDRA version: 9.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusEUCTR2006-006550-96-ITIDDK TYPE 1 DIABETES TRIALNET300
进行中（未招募）
1 期
ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETES MELLITUSOral insulin is to be used for the prevention of type 1 diabetes mellitus in relatives at risk of developing the disease.MedDRA version: 18.0Level: PTClassification code 10066284Term: Diabetes prophylaxisSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2006-006550-96-FITrialNet Study Group300
进行中（未招募）
1 期
Dasiglucagon for Prevention of Low Blood Glucose Levels in People with Type 1 DiabetesType 1 diabetesMedDRA version: 21.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2020-000551-12-DKSteno Diabetes Center Copenhagen20
进行中（未招募）
1 期
Insulin Therapy for the Prevention of New Onset Diabetes after Transplantation - Prospective Study in Non-Diabetic De Novo Kidney Transplant RecipientsEUCTR2012-000225-51-ATMedizinische Universität Wien Universitätsklinik für Innere Medizin III380